174 results
P
wild population, female germplasm, oocytes, embryos, endangered species
I/C
preservation, biotechnological tool, Assisted Reproductive Technology (ART), artificial insemination (AI), embryo transfer technology (ETT), sperm cryopreservation, cryopreservation techniques, vitrification, domestic animal female genetic material, wild animals
O
conservation of biodiversity, preservation of vital tissues, economical and easily applied
P
patients with allergic rhinitis
I/C
oral H, placebo
O
total symptom score reduction, nasal congestion score reduction, rhinorrhea score reduction, ocular symptom score reduction, nasal itching score reduction, sneezing score reduction
P
541 participants
I/C
periodontal treatment, conventional systemic H. pylori eradication therapy alone
O
gastric H. pylori eradication rates
P
animals
I/C
hypothermic machine perfusion, subnormothermic machine perfusion, warm ischemia without cold storage, normothermic machine perfusion, static cold storage (< 12 h), warm ischemia without cold storage, normothermic machine perfusion, static cold storage (< 12 h), static cold storage (≥ 12 h)
O
ATP content, respiratory activity of mitochondrial complexes, cytochrome c release, aspartate aminotransferase (ALT) release
P
working-age (≥15 years) workers in the formal and informal economy
I/C
exposure to long working hours (41-48, 49-54 and ≥55 h/week), exposure to standard working hours (35-40 h/week)
O
depression (prevalence, incidence and mortality)
P
adults with advanced RAS wild-type CRC
I/C
induction combination chemotherapy doublets (CT) with an anti-EGFR agent, depotentiation treatments
O
overall survival (OS)
P
Helicobacter pylori (H. pylori) positive peptic ulcer disease (PUD)
I/C
Chinese herbal formulae, conventional triple therapy (CON)
O
eradication rate, clinical efficiency, recurrence rate
P
adult individuals
I/C
low-sodium salt substitute (LSSS), no LSSS
O
lower 24-h urinary sodium excretion
P
adult participants undergoing hip surgery
I/C
quadratus lumborum block (QLB), no block
O
postoperative 24-h opioid consumption, 12-h/24-h visual analog scale (VAS) or numeric rating scale (NRS) pain scores, postoperative nausea and vomiting (PONV), satisfaction
P
advanced wild-type non-small cell lung cancer (NSCLC) patients
I/C
immune checkpoint inhibitors (ICIs), programmed death 1 (PD-1)/programmed death-ligand 1 (PD-L1) or cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) inhibitors ± chemotherapy (CT), double ICIs (DICI)-based treatments, single ICI (SICI)-based treatments
O
overall survival (OS), progression-free survival (PFS), objective response rate (ORR), grade 3 or higher adverse events (≥3AEs)